Suhrkamp Ina, Scheffold Alexander, Heine Guido
Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.
Institute of Immunology, University Hospital Schleswig-Holstein, Kiel, Germany.
Eur J Immunol. 2023 Oct;53(10):e2249983. doi: 10.1002/eji.202249983. Epub 2023 Aug 2.
Antigen-specific T lymphocytes are the central regulators of tolerance versus immune pathology against otherwise innocuous antigens and key targets of antigen-specific immune therapy. Recent advances in the understanding of T cells in tolerance and allergy resulted from improved technologies to directly characterize allergen-specific T cells by multiparameter flow cytometry or single-cell sequencing. This unravelled phenotypically and functionally distinct populations, such as Type 2a T helper cells (Th2a), follicular Th cells (Tfh), regulatory T cells (Treg), Type 1 regulatory T cells (Tr1), and follicular T regulatory cells. Here we will discuss the role of the different Th-cell subsets in the healthy state, during sensitization and development of allergy, and in tolerance induction by allergen immunotherapy (AIT). To date, the mechanisms of AIT as the only causal treatment of allergy are not completely understood. The analyses of allergen-specific T cells directly ex vivo during AIT support the concept of specific-Th2(a) cell deletion rather than an expansion of allergen-specific Tr1 or Treg cells as underlying mechanism.
抗原特异性T淋巴细胞是针对原本无害抗原的免疫耐受与免疫病理的核心调节因子,也是抗原特异性免疫治疗的关键靶点。通过多参数流式细胞术或单细胞测序直接鉴定变应原特异性T细胞的技术取得进展,推动了对T细胞在免疫耐受和过敏方面的理解。这揭示了表型和功能上不同的细胞群体,如2a型辅助性T细胞(Th2a)、滤泡辅助性T细胞(Tfh)、调节性T细胞(Treg)、1型调节性T细胞(Tr1)和滤泡调节性T细胞。在此,我们将讨论不同Th细胞亚群在健康状态、过敏致敏和发展过程中以及在变应原免疫治疗(AIT)诱导免疫耐受中的作用。迄今为止,作为唯一能够治愈过敏的AIT的作用机制尚未完全明确。对AIT期间直接取自体内的变应原特异性T细胞的分析支持了特异性Th2(a)细胞缺失的概念,而非变应原特异性Tr1或Treg细胞的扩增作为潜在机制。